Activity of imipenem/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam resistant mutants.
Imipenem and Imipenem/relebactam MICs were determined for 1,445 P. aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem/relebactam showed highest susceptibility rates (97.3%), followed by colistin and ceftolozane/tazobactam (both 94.6%). Imipenem/relebactam MICs remained ≤2 μg/mL in all 16 isogenic PAO1 mutants and in 8 pairs of XDR clinical strains that had developed resistance to ceftolozane/tazobactam and ceftazidime/avibactam due to mutations in OXA-10 or AmpC.